J&J reports promising Ebola vaccine data
Johnson & Johnson said on Monday (Sept 13) its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal. The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98 per cent of all participants,...